GB2113546A - Treatment of migraine - Google Patents
Treatment of migraine Download PDFInfo
- Publication number
- GB2113546A GB2113546A GB08201911A GB8201911A GB2113546A GB 2113546 A GB2113546 A GB 2113546A GB 08201911 A GB08201911 A GB 08201911A GB 8201911 A GB8201911 A GB 8201911A GB 2113546 A GB2113546 A GB 2113546A
- Authority
- GB
- United Kingdom
- Prior art keywords
- levo
- migraine
- paracetamol
- hydroxytryptophan
- tryptophan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 16
- 206010027599 migraine Diseases 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 title claims description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960005489 paracetamol Drugs 0.000 claims abstract description 17
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims abstract description 15
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000000202 analgesic effect Effects 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 5
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims abstract description 3
- 230000001154 acute effect Effects 0.000 claims description 6
- 229940035676 analgesics Drugs 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002460 anti-migrenic effect Effects 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 239000006194 liquid suspension Substances 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions for treating migraine comprise a mixture of 1-tryptophan or 5-hydroxytryptophan and a peripherally acting analgesic e.g. paracetamol.
Description
SPECIFICATION
Pharmaceutical composition This invention relates to pharmaceutical compositions for the treatment of migraine.
Migraine, in both its common and classical forms, and its associated disorders, is estimated to affect from 8-12% of the population. Numerous compounds have been proposed for the treatment of migraine both on a preventative basis and on an acute basis, but the need still exists for an effective anti-migraine treatment.
In accordance with the present invention, it has been found that levo-tryptophan, or levo - 5 hydroxytryptophan, which is known metabolite of levo-tryptophan, is a useful adjunct two peripherally acting analgesics such as paracetamol, in the alleviation of the acute symptoms of migraine. The use of levo-tryptophan in migranetreatment has been discussed in some detail in 'headache', Volume 18,
No.3, (July 1978) page 161, but combination thereby in conjunction with peripherally acting analgesics is not discussed.
In one aspect, the present invention provides a pharmaceutical composition for the treatment of migraine comprising in admixture levo-tryptophan, or levo - 5 - hydroxytryptophan, and a peripherally acting analgesic, preferably paracetamol.
In another aspect, the present invention provides a method of alleviating the acute symptoms of mig rainewhich comprises administering both levotryptophan, or levo - 5 - hydroxytryptophan, and a peripherally, acting analgesic, preferably paracetamol.
The pharmaceutical compositions of the present invention are preferably in tablet form for oral administration comprising levo-tryptophan, or levo 5 - hydroxytryptophan, and the peripherally acting analgesic, e.g. paracetamol, in admixture in a tabletting carrier.
In the combination therapy ofthe present invention the effective dose range of levo-tryptophan, or levo - 5 - hydroxytryptophan is from 5-3000 mgs, four to six hourly, preferably 500-1500 mgs, and from 50-1500 mgs paracetamol. Tablets for oral administration will be formulated accordingly, conveniently each as a single dosage unit containing from 5-3000 mgs, preferably 5-1500 mgs, levo-tryptophan, or levo - 5 hydroxytryptophan, and from 50-1500 mgs paracetamol.
Otherformulations, e.g. liquid suspensions, for oral orfor rectal administration will be obvious to those skilled in the art.
Instead of paracetamol, other p-aminophenols having peripheral analgesic activity may be used.
The pharmaceutical compositions of the invention may also include other active ingredients, for example, caffeine, and as migraine is often associated with gastric stress drug, such as metaclopramide, which restores gastric mobility, increase drug absorption and reduce nausea, can be added.
1. A pharmaceutical composiiton fo r the treat- ment of migraine comprising in admixture levotryptophan, or levo - 5 - hydroxytryptophan and a peripherally acting analgesic.
2. A composition according to claim 3, wherein the analgesic is paracetamol.
3. A composition according to any one of the preceding claims in tablet form.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (3)
1. A pharmaceutical composiiton fo r the treat- ment of migraine comprising in admixture levotryptophan, or levo - 5 - hydroxytryptophan and a peripherally acting analgesic.
2. A composition according to claim 3, wherein the analgesic is paracetamol.
3. A composition according to any one of the preceding claims in tablet form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08201911A GB2113546A (en) | 1982-01-22 | 1982-01-22 | Treatment of migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08201911A GB2113546A (en) | 1982-01-22 | 1982-01-22 | Treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2113546A true GB2113546A (en) | 1983-08-10 |
Family
ID=10527833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08201911A Withdrawn GB2113546A (en) | 1982-01-22 | 1982-01-22 | Treatment of migraine |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2113546A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988004170A1 (en) * | 1986-12-13 | 1988-06-16 | Joachim Kamprad | Pain-killer |
| WO1999023881A1 (en) * | 1997-11-12 | 1999-05-20 | Allocca Technical, Inc. | Composition and method for preventing or alleviating migraine headaches |
| US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| WO2018071656A1 (en) * | 2016-10-14 | 2018-04-19 | Knowles Enterprises Inc. | Formulations for treatment of migraines |
-
1982
- 1982-01-22 GB GB08201911A patent/GB2113546A/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988004170A1 (en) * | 1986-12-13 | 1988-06-16 | Joachim Kamprad | Pain-killer |
| US5216019A (en) * | 1986-12-13 | 1993-06-01 | Joachim Kamprad | Pain killer |
| JPH0645539B2 (en) | 1986-12-13 | 1994-06-15 | カンプラート、ヨアヒム | Painkiller |
| US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| WO1999023881A1 (en) * | 1997-11-12 | 1999-05-20 | Allocca Technical, Inc. | Composition and method for preventing or alleviating migraine headaches |
| US5939076A (en) * | 1997-11-12 | 1999-08-17 | Allocca Techical, Inc. | Composition and method for treating or alleviating migraine headaches |
| GB2348133A (en) * | 1997-11-12 | 2000-09-27 | Allocca Technical Inc | Composition and method for preventing or alleviating migraine headaches |
| WO2018071656A1 (en) * | 2016-10-14 | 2018-04-19 | Knowles Enterprises Inc. | Formulations for treatment of migraines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ288298A (en) | Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors | |
| RU94040864A (en) | Fused indole derivatives, their synthesis, pharmaceutical composition | |
| RU94041223A (en) | Agent for motoneuron disease treatment | |
| BR9908030A (en) | Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated | |
| BR9612423A (en) | Compound, pharmaceutical composition, and process for treating an unhealthy condition. | |
| RU94002337A (en) | Pharmaceutical composition, use of gamma-linolenic acid or dihomo-gamma-linolenic acid for damage treatment after irradiation, treatment method | |
| CA2150185A1 (en) | Pharmaceutical composition for the treatment of stoma-peripheral inflammation | |
| RU94045278A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for vasomotor symptom and associated psychological disorder inhibition associated with postclimacteric syndrome | |
| DE69733089D1 (en) | Treatment of osteotarthritis by administration of poly-N-acetyl-D-glucosamine | |
| MX173567B (en) | PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION TO IMPROVE THE SYMPTOMS OF HIV-INDUCED DISEASE OR REDUCE HIV TRANSCRIPTION AND PROLIFERATION | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| MX9403088A (en) | Indole derivatives. | |
| RU94045866A (en) | Use of bis-phenylalkylpiperazines for treatment of disorders caused by substance abuse, method of treatment | |
| JPS5234935A (en) | Medicinal composition | |
| RU94044438A (en) | Use of 2-phenyl-3-aroylbenzthiophenes for contraception suppression in women | |
| GB2113546A (en) | Treatment of migraine | |
| US3008874A (en) | Pharmaceutical compositions | |
| CA2150183A1 (en) | Pharmaceutical composition for the treatment of hemorrhoidal diseases | |
| FR2500303B1 (en) | ||
| IL109076A0 (en) | Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them | |
| IL70407A (en) | Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine | |
| GB2113545A (en) | Treatment of migraine | |
| RU94032792A (en) | Application of 5htia-antagonists for tobacco use stopping | |
| GB2113544A (en) | Treatment of migraine | |
| US4885288A (en) | Pharmaceutical compositions containing lysine acetylsalicylate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |